Loading…
Biotech selling Arcalyst, an interleukin blocker for recurrent pericarditis, a rare heart-lining inflammation.
Biotech selling Arcalyst, an interleukin blocker for recurrent pericarditis, a rare heart-lining inflammation.
Sells Arcalyst as a weekly injection, taken by patients for years through specialty pharmacies, so revenue grows as more people are diagnosed and stay on treatment. It licenses Arcalyst from Regeneron, which makes the drug and receives payments in return, so a share of each sale goes back to its originator.
Moat: narrow (IP / patents, regulatory licence). First and only approved therapy specifically for recurrent pericarditis, with orphan-drug protection.
Headquarters: Lexington, Massachusetts, United States · Founded: 2015 · Employees: 366
Size Kiniksa Pharmaceuticals International (KNSA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.37B, the 935th largest of 3,117 United States companies the cockpit tracks. Shares closed at $93.86 on 6 Nov 2026.
Performance Over six months the shares gained 60.2%, against +3.7% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 58.2% over the last twelve months (peer median +9.1%); the operating margin is 13.8% (peer median 16.9%).
Valuation It trades at 61.7× forward earnings against a peer median of 16.4× (most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +45%, so the hurdle is -36 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 62.7 points above its cost of capital (6.4% WACC).
Short interest Short interest is 7.8% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $946M | $678M | $423M | $270M | $220M |
| Revenue growth | — | +60% | +57% | +23% | — |
| Gross profit | $513M | $370M | $234M | $179M | $169M |
| EBITDA | $132M | $78.8M | -$43.9M | -$23.1M | $14.0M |
| Net income | $110M | $59.0M | -$43.2M | $14.1M | $183M |
| Free cash flow | $197M | $136M | $25.4M | $13.2M | $5.70M |
| Capital expenditure | $1.64M | $1.57M | $277,000 | $130,000 | $105,000 |
| Total debt | $7.88M | $9.50M | $9.86M | $12.3M | $5.92M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals International KNSA | $7.37B | +60% | +58% | 14% | 61.7× | 9.9% |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 18.4× | 1.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KNSA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.2% | +3.2% | 3rd highest of 21 |
| 6-month return | +60.2% | +3.7% | highest of 21 |
| Distance from 52-week high | -4.7% | -11.5% | 4th highest of 21 |
| Revenue growth (TTM) | +58.2% | +9.1% | 3rd highest of 20 |
| Operating margin | 13.8% | 16.9% | 8th lowest of 19 |
| Forward P/E | 61.7× | 16.4× | most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 9.9% | 6.8% | 6th most demanding of 14 |
| Growth delivered (Del g) | +45.5% | +9.3% | 2nd highest of 14 |
| Hurdle (Req g minus delivered) | -35.5 pp | -5.0 pp | 2nd least demanding of 14 |
| ROIC minus cost of capital | +62.7 pp | +1.6 pp | 2nd highest of 20 |
| EV / EBITDA | 51.5× | 17.4× | 2nd most expensive of 12 |
| Net debt / EBITDA | -4.2× | -0.1× | least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 61.7× | 9.9% | +45.5% |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 33.1× | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 14.0× | -2.7% | +5.3% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | n/a | n/a | n/a |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% | +7.1% |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | n/a | 31.5% | +7.3% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 32.0× | 20.0% | +9.4% |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 17.7× | 15.2% | +8.7% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 14.7× | -8.2% | +10.8% |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | n/a | n/a | n/a |
| RemeGen 9995.HK | Hong Kong | $6.92B | -31% | +293% | 61% | 7.4× | -4.8% | +57.9% |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 16.4× | 24.9% | +16.6% |
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | n/a | -9.1% | +6.6% |
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 15.6× | -6.1% | +9.3% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $8.07B | +23% | +18% | 17% | 41.4× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 35.7× | 7.6% | +12.6% |
| Alkem Laboratories ALKEM.NS | India | $6.67B | -5% | +13% | 17% | 27.4× | 24.3% | +10.7% |
| Ionis Pharmaceuticals IONS | United States | $6.55B | -48% | -7% | -68% | n/a | n/a | n/a |
| Shanghai Pharmaceuticals 601607.SS | China | $8.32B | -2% | +4% | 3% | 11.4× | -10.0% | +8.1% |